607375-34-8

Basic information

• Product Name: (3S,4R)-4-(4-fluorophenyl)-1-(4-methoxyphenyl)-2-oxopiperidin-3-carboxylic acid methyl ester
• Synonyms: (3S,4R)-4-(4-fluorophenyl)-1-(4-methoxyphenyl)-2-oxopiperidin-3-carboxylic acid methyl ester
• CAS NO: 607375-34-8
• Molecular Weight: 357.382
• Mol File: 607375-34-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (3S,4R)-4-(4-fluorophenyl)-1-(4-methoxyphenyl)-2-oxopiperidin-3-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,4R)-4-(4-fluorophenyl)-1-(4-methoxyphenyl)-2-oxopiperidin-3-carboxylic acid methyl ester(607375-34-8)
• EPA Substance Registry System: (3S,4R)-4-(4-fluorophenyl)-1-(4-methoxyphenyl)-2-oxopiperidin-3-carboxylic acid methyl ester(607375-34-8)

Safety Data

• Hazardous Substances Data: 607375-34-8(Hazardous Substances Data)

Upstream product

• 1027570-33-7 N-[3-(4-fluoro-phenyl)-3-oxo-propyl]-N-(4-methoxy-phenyl)-malonamic acid ethyl ester 
• 607375-32-6 4-(4-fluorophenyl)-1-(4-methoxyphenyl)-5,6-dihydro-1H-pyridin-2-one 
• 104-94-9 4-methoxy-aniline 
• 37155-08-1 1-(4-fluorophenyl)-3-(4-methoxyphenylamino)propan-1-one 
• 616-38-6 carbonic acid dimethyl ester 
• 607375-33-7 (4R)-4-(4-fluorophenyl)-1-(4-methoxyphenyl)-piperidin-2-one 

Downstream Products

• 125224-43-3 (3S,4R)-trans-4-(4-fluorophenyl)-3-hydroxymethylpiperidine 
• 200572-35-6 (3S,4R)-1-(tert-butoxycarbonyl)-4-(p-fluorophenyl)-3-[3,4-(methylenedioxy)phenoxymethyl]piperidine 
• 200572-33-4 (3S,4R)-4-(4-fluorophenyl)-3-hydroxymethylpiperidine-1-carboxylic acid tert-butyl ester 
• 61869-08-7 paroxetine 
• 607375-35-9 [(3S,4R)-4-(4-fluorophenyl)-1-(4-methoxyphenyl)-piperidin-3-yl]methanol 

Relevant articles and documents

Catalytic enantioselective conjugate reduction of lactones and lactams

A dramatic acceleration of the enantioselective copper-catalyzed conjugate reduction of α,β-unsaturated lactones, lactams, and esters is reported upon addition of alcohol additives. Good to excellent yields and enantioselectivities were realized using a catalyst generated in situ from CuCl2·H2O, t-BuONa, p-tol-BINAP, and PMHS, and this methodology was applied to the synthesis of (-)-Paroxetine.